Anteris Technologies Global Corp. (NASDAQ: AVR) is a Healthcare company (Medical - Devices) with a market capitalization of $571M. The Maz Rating grades it against the other companies in its sector.
About three months ago (July 2, 2026), Anteris Technologies Global Corp. had a Maz Rating of 4.67 out of 5 (A, Strong Buy), ranked against the other companies in its sector. Its strongest factor then was Momentum (4.78), among the strongest in its sector; its weakest was Profitability (2.17), below most of its sector. The other factors: Financial Health 4.24 (above most of its sector); Growth 3.88 (above most of its sector); Valuation 2.61 (valued in line with its sector). The current rating is for members: log in to see it.
At $5.86, Anteris Technologies Global Corp. trades at 248.5x sales and 2.6x book value. Over the last twelve months it generated about $2M of revenue and a net loss of $202M. It runs a gross margin of 39.3%, an operating margin of -4880.4% and a net margin of -4637.9%. It shows return on equity of -57.2%, return on invested capital of -46.6% and a free cash flow yield of -16.4%. On the balance sheet: a debt-to-equity ratio of 0.07 and a current ratio of 12.45. Over the past 52 weeks the share price ranged from $3.30 to $11.06, with a beta of 0.73.
Anteris Technologies Global Corp. does not currently pay a dividend.
2 Wall Street analyst ratings cover the stock: 2 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.